Literature DB >> 3290286

Pemphigus.

N Korman1.   

Abstract

The term pemphigus refers to a group of autoimmune intraepidermal blistering diseases of the skin and mucous membranes. Several clinical variants of pemphigus are recognized. The major histologic feature of all variants is acantholysis, the disruption of normal cell-to-cell adhesion, which leads to intraepidermal blister formation. Most patients with pemphigus demonstrate IgG autoantibodies directed against an antigen located on the surface of keratinocytes. Although the stimulus for autoantibody production is unknown, several mechanisms have been proposed to explain the pathogenesis of acantholysis. One popular model proposes that pemphigus antibodies induce acantholysis through local stimulation of the plasminogen-plasmin system. Another model proposes that pemphigus antibodies fix complement and thereby alter cell membrane integrity to produce acantholysis. Prior to the availability of corticosteroids, pemphigus vulgaris was commonly fatal. Treatment with glucocorticosteroids has drastically improved the prognosis. Immunosuppressive agents and plasmapheresis have been used successfully in some patients with severe disease.

Entities:  

Mesh:

Year:  1988        PMID: 3290286     DOI: 10.1016/s0190-9622(88)70128-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

1.  Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris.

Authors:  A R Ahmed; R Wagner; K Khatri; G Notani; Z Awdeh; C A Alper; E J Yunis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  An unusual presentation of pemphigus vulgaris.

Authors:  Jesse P Houghton; Monica Ianosi-Irimie; Stacey B Trooskin; Hazar Michael
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

3.  Elevated expression of NLRP1 and IPAF are related to oral pemphigus vulgaris pathogenesis.

Authors:  Reza Mahvelati Shamsabadi; Soroush Basafa; Reza Yarahmadi; Samaneh Goorani; Masood Khani; Maryam Kamarehei; Amir Hossein Kiani
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

4.  Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris.

Authors:  A R Ahmed; E J Yunis; K Khatri; R Wagner; G Notani; Z Awdeh; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Cicatricial changes in ocular pemphigus.

Authors:  P Chirinos-Saldaña; I Zuñiga-Gonzalez; J C Hernandez-Camarena; A Navas; T Ramirez-Luquin; A Robles-Contreras; M C Jimenez-Martinez; A Ramirez-Miranda; V M Bautista-de Lucio; E O Graue-Hernandez
Journal:  Eye (Lond)       Date:  2014-01-31       Impact factor: 3.775

6.  Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid.

Authors:  Anjela Galan; Pei Hui; Jennifer M McNiff
Journal:  Int J Clin Exp Pathol       Date:  2009-01-30

7.  Triamcinolone acetonide for rare ocular manifestations of pemphigus vulgaris: a case report.

Authors:  N Kozeis; S Tyradellis; E Dragiotis; H Eleftheriadis
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  High levels of anti-heat shock protein 27 antibody in pemphigus vulgaris.

Authors:  Mohammad Javad Yazdanpanah; Ali Reza Taji; Zari Javidi; Fakhrozaman Pezeshkpoor; Amir Ali Rahsepar; Shima Tavallaie; Akram Momenzadeh; Saber Shojaie-Noori; Mohsen Khoddami; Sara Rahsepar; Majid Ghayour-Mobarhan; Gordon Ashley Anthony Ferns
Journal:  Ann Dermatol       Date:  2013-05-10       Impact factor: 1.444

9.  Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.

Authors:  K Bhol; K Natarajan; N Nagarwalla; A Mohimen; V Aoki; A R Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

10.  Pemphigus: active or inactive?

Authors:  Jignesh B Vaishnani; Sanjay S Bosamiya
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.